Clinical Trial

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability and preliminary activity of IEV407 as a single agent and in combination with endocrine therapy (fulvestrant or letrozole) in patients with advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-negative) breast cancer.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-28
Trial Details
NCT Number NCT07604571
Lead Sponsor Novartis Pharmaceuticals
Conditions Advanced HR+/HER2- Breast Cancer
Enrollment 194 participants
Start Date 2026-05-28
Primary Completion 2032-06-08 (estimated)
Study Completion 2032-06-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-30